Results 141 to 150 of about 71,934 (217)

Arrhythmic Risk in Carriers of Predicted Deleterious Rare Variants in Dilated and Arrhythmogenic Cardiomyopathy Genes. [PDF]

open access: yesJACC Adv
Gandin I   +11 more
europepmc   +1 more source

Long‐Term Use of Rezafungin: A Case Report and Insights Into Real‐World Access

open access: yes
Transplant Infectious Disease, EarlyView.
Jian Mei Li   +2 more
wiley   +1 more source

A Large‐Scale Cross‐Population Evaluation of Genetic Risk Variants for Dilated Cardiomyopathy in Dobermanns

open access: yesAnimal Genetics, Volume 57, Issue 5, October 2026.
ABSTRACT Previous studies suggest that genetic risk factors for dilated cardiomyopathy (DCM) in Dobermann dogs may differ between populations, complicating the use of genetic tests across subpopulations. Variants in pyruvate dehydrogenase kinase 4 (PDK4) and titin (TTN) have been associated with DCM in North American Dobermanns, whereas two loci on ...
Alma H. Hulsman   +15 more
wiley   +1 more source

De Novo 2.2 Mb 19q13.42–q13.43 Microdeletion Encompassing U2AF2: Support for a Haploinsufficiency Model

open access: yesAmerican Journal of Medical Genetics Part A, Volume 200, Issue 10, Page 2350-2356, October 2026.
ABSTRACT U2 small nuclear RNA auxiliary factor 2 (U2AF2) is an essential pre‐mRNA splicing factor involved in the early stages of pre‐mRNA splicing. To date, multiple individuals have been reported with predominantly heterozygous missense variants presenting intellectual disability, speech and motor delays, seizures, hypotonia, and thin or hypoplastic ...
Amanda Toledo   +3 more
wiley   +1 more source

Genetic Testing After Heart Transplantation Uncovers Heritable Disease and Drives Family Screening. [PDF]

open access: yesJACC Adv
Moliner-Abós C   +33 more
europepmc   +1 more source

Lung‐Cardiovascular Interactions and Derangements in ARDS

open access: yesComprehensive Physiology, Volume 16, Issue 5, October 2026.
This review proposes an anatomical near‐ and far‐field framework for lung‐cardiovascular interactions in ARDS. Grounded in pathological and biological studies, the evidence spans pulmonary vascular, right ventricular, and systemic endothelial derangements and reviews available evidence for targeted therapies.
Pablo A. Sanchez   +4 more
wiley   +1 more source

SGLT2i in heart failure: Cardiorenal mechanisms, clinical evidence and translational perspectives

open access: yesClinical and Translational Discovery, Volume 6, Issue 5, October 2026.
SGLT2 inhibitors improve heart failure outcomes through integrated cardiorenal mechanisms. In the kidney, they reduce glucose and sodium reabsorption, promoting natriuresis, osmotic diuresis and renal protection. In the heart, they enhance myocardial energetics, reduce inflammation, oxidative stress, fibrosis and adverse remodelling, resulting in fewer
Jelica Grujic‐Milanovic   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy